--- title: "Dilution, Definition | MedTech Terms" description: "Reduction in existing shareholder ownership when new shares are issued. Plain-English Investment & Finance definition for MedTech teams, with examples and relat" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/dilution#term", "name": "Dilution", "description": "Dilution is the percentage decrease in an existing shareholder's ownership stake caused by the issuance of new shares - through a financing, option grants, SAFE conversion, or warrant exercise.", "url": "https://medtechterms.com/terms/dilution", "termCode": "dilution", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/dilution#article", "headline": "Dilution", "description": "Reduction in existing shareholder ownership when new shares are issued.", "url": "https://medtechterms.com/terms/dilution", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/dilution" }, "about": { "@id": "https://medtechterms.com/terms/dilution#term" }, "articleSection": "Investment & Finance", "inLanguage": "en", "keywords": "Dilution, Investment & Finance, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "Carta: founder dilution", "url": "https://carta.com/learn/startups/equity-management/dilution/", "publisher": { "@type": "Organization", "name": "Carta" } }, { "@type": "CreativeWork", "name": "PitchBook - MedTech Coverage", "url": "https://pitchbook.com/news/articles/topic/healthtech", "publisher": { "@type": "Organization", "name": "PitchBook" } }, { "@type": "CreativeWork", "name": "NVCA Model Documents", "url": "https://nvca.org/model-legal-documents/", "publisher": { "@type": "Organization", "name": "NVCA" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/cap-table#term", "name": "Capitalization Table", "alternateName": "Cap Table", "url": "https://medtechterms.com/terms/cap-table" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/anti-dilution#term", "name": "Anti-Dilution Protection", "url": "https://medtechterms.com/terms/anti-dilution" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/option-pool#term", "name": "Employee Option Pool", "url": "https://medtechterms.com/terms/option-pool" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Investment & Finance", "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance" }, { "@type": "ListItem", "position": 4, "name": "Dilution", "item": "https://medtechterms.com/terms/dilution" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/dilution#faq", "mainEntity": [ { "@type": "Question", "name": "How does dilution affect regulatory submissions?", "acceptedAnswer": { "@type": "Answer", "text": "While dilution doesn't directly alter the technical content of a regulatory submission, significant ownership changes may require updating administrative sections, particularly those identifying the legal manufacturer or authorized representative. This could be relevant for submissions to the FDA or under the EU MDR." } }, { "@type": "Question", "name": "Can dilution impact a company's quality management system (QMS)?", "acceptedAnswer": { "@type": "Answer", "text": "Indirectly, yes. Changes in ownership can lead to shifts in company priorities, resources, or management, which can affect the funding and support for maintaining and improving the QMS, as required by standards like ISO 13485 or 21 CFR 820." } }, { "@type": "Question", "name": "Is dilution a cybersecurity concern?", "acceptedAnswer": { "@type": "Answer", "text": "While not a direct cybersecurity event, a change in ownership due to dilution could introduce new stakeholders with different cybersecurity risk appetites or practices. This might necessitate a review of existing cybersecurity policies and procedures to ensure continued alignment with frameworks like NIST CSF or requirements under GDPR for data protection." } }, { "@type": "Question", "name": "Does the FDA have rules about dilution?", "acceptedAnswer": { "@type": "Answer", "text": "The FDA does not directly regulate financial dilution. However, it is concerned with the legal manufacturer and the entity responsible for the medical device, which could be impacted by changes in ownership resulting from dilution. For example, any change affecting the legal manufacturer's name or address would need to be communicated to the FDA as per relevant guidance." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Investment & Finance](/terms?cat=Investment%20%26%20Finance) 6. / 7. Dilution [All terms](/terms) Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle) # Dilution Reduction in existing shareholder ownership when new shares are issued. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Dilution is the percentage decrease in an existing shareholder's ownership stake caused by the issuance of new shares - through a financing, option grants, [SAFE](/terms/safe-note) conversion, or warrant exercise. What the regulation says While dilution primarily concerns investment and finance, it can indirectly impact MedTech regulatory and quality aspects. For instance, significant changes in ownership structure due to dilution might trigger re-evaluation of the designated authorized representative for EU [MDR](/terms/mdr-reporting) compliance, or impact resource allocation for maintaining a robust quality management system under 21 CFR 820. Changes in company control could also necessitate reviewing data privacy agreements under [HIPAA](/terms/hipaa) or GDPR if new entities gain access to patient data. ## What this means in practice MedTech companies typically dilute 20–25% per priced round. Founders who raise 6–8 rounds before exit can end up with single-digit ownership. Capital-efficient milestones - anything that lets you raise less or at higher valuations - directly preserve founder equity. ## Examples - A MedTech startup undergoes a Series B funding round, diluting existing shareholders to fund a critical clinical trial required for FDA premarket approval (PMA). - A company's ownership structure changes significantly after a large equity investment, leading to a re-evaluation of the notified body contract under the EU MDR requirements. - New investors join a medical device company through share issuance, prompting a review of the budget allocated for maintaining ISO 13485 certification and post-market surveillance activities. Common pitfalls - • Confusing financial dilution with product-related dilution, which refers to reducing the concentration of a substance. - • Underestimating how dilution affects long-term strategic decisions, including budget allocation for regulatory affairs and quality assurance. - • Failing to consider the impact of ownership changes on existing regulatory submissions and approvals, such as marketing authorizations or notified body certifications. - • Overlooking the potential for new investors to influence risk management strategies, thereby impacting compliance with ISO 14971. - • Not adequately communicating ownership changes to relevant regulatory bodies when such changes affect legal manufacturer status or authorized representation. ## Frequently asked questions How does dilution affect regulatory submissions? While dilution doesn't directly alter the technical content of a regulatory submission, significant ownership changes may require updating administrative sections, particularly those identifying the legal manufacturer or authorized representative. This could be relevant for submissions to the FDA or under the EU [MDR](/terms/mdr-reporting). Can dilution impact a company's quality management system (QMS)? Is dilution a cybersecurity concern? Does the FDA have rules about dilution? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Investment & Finance Anti-Dilution Protection Adjustment that protects investors if the company raises a future round at a lower price. ](/terms/anti-dilution)[ Investment & Finance Capitalization Table(Cap Table) Ledger of all securities issued by a company and who owns them. ](/terms/cap-table)[ Investment & Finance Employee Option Pool Shares reserved for issuance to employees as stock options. ](/terms/option-pool) ### More in Investment & Finance · Same category [ Investment & Finance 409A Valuation An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options. ](/terms/409a-valuation)[ Investment & Finance Bridge Round Interim financing between priced rounds, usually convertible. ](/terms/bridge-round)[ Investment & Finance Burn Rate Rate at which a company spends cash, typically expressed monthly. ](/terms/burn-rate)[ Investment & Finance Burn Rate and Runway Monthly net cash consumption (burn) and months of cash remaining (runway). ](/terms/burn-runway) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 Carta· 1 PitchBook· 1 NVCA· 1 1. [1 Carta: founder dilution Verified Carta · carta.com ](https://carta.com/learn/startups/equity-management/dilution/) 2. [2 PitchBook - MedTech Coverage Verified PitchBook · pitchbook.com ](https://pitchbook.com/news/articles/topic/healthtech) 3. [3 NVCA Model Documents Verified NVCA · nvca.org ](https://nvca.org/model-legal-documents/) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Diligencing a MedTech cybersecurity posture? Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Investment & Finance Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=dilution) Learn in 60 seconds Card Lesson Quiz Reduction in existing shareholder ownership when new shares are issued. - · MedTech companies typically dilute 20–25% per priced round. - · Founders who raise 6–8 rounds before exit can end up with single-digit ownership. - · Capital-efficient milestones - anything that lets you raise less or at higher valuations - directly preserve founder equity. Remember this Watch out: Confusing financial dilution with product-related dilution, which refers to reducing the concentration of a substance. Related terms - [Capitalization Table(Cap Table) ](/terms/cap-table) - [Anti-Dilution Protection ](/terms/anti-dilution) - [Employee Option Pool ](/terms/option-pool) You may also need Auto-suggested from Investment & Finance and shared keywords. - [Pre-Money Valuation ](/terms/pre-money-valuation) - [Pro-Rata Rights ](/terms/pro-rata-rights) - [Simple Agreement for Future Equity(SAFE) ](/terms/safe-note) - [409A Valuation ](/terms/409a-valuation) - [Bridge Round ](/terms/bridge-round) - [Down Round ](/terms/down-round) [All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)